An interpretable machine learning approach for predicting drug-resistant epilepsy in children with tuberous sclerosis

Jie Fu1,2, Genfu Zhang1,2, Zhixian Yang1,2

  • 1Department of Pediatrics, Peking University People's Hospital, Beijing, China.

Frontiers in Neurology
|August 20, 2025
PubMed

Insights

This study created a machine learning model to predict drug-resistant epilepsy (DRE) in children with Tuberous Sclerosis Complex (TSC). Early identification of DRE risk in pediatric TSC patients is now more accurate.

Area of Science:

  • Computational neuroscience
  • Pediatric neurology
  • Machine learning in medicine

Background:

  • Tuberous Sclerosis Complex (TSC) is a genetic disorder associated with epilepsy.
  • Drug-resistant epilepsy (DRE) poses a significant challenge in managing pediatric TSC.
  • Predictive tools for DRE risk in TSC are crucial for timely intervention.

Purpose of the Study:

  • To develop and validate an interpretable machine learning (ML) algorithm for predicting DRE risk in children with TSC.
  • To enhance the transparency and clinical utility of predictive models for DRE in pediatric TSC.

Main Methods:

  • Retrospective collection of clinical data from 88 pediatric patients with TSC-related epilepsy.
  • Application of 9 ML algorithms, including Random Forest (RF), to build predictive models.
  • Utilizing SHapley Additive exPlanations (SHAP) for model interpretability and feature importance analysis.

Main Results:

  • The RF model demonstrated superior performance with an AUC of 0.862 and specificity of 0.930.
  • Identified key predictors of DRE: infantile epileptic spasms syndrome (IESS) history, multifocal EEG discharges, multiple cortical tubers, and polypharmacy (≥3 ASMs).
  • Validated model performance through tenfold cross-validation and decision curve analysis (DCA), confirming clinical utility.

Conclusions:

  • The developed RF-based prediction model aids in the early identification of children with TSC at high risk for DRE.
  • Improved model interpretability via SHAP facilitates individualized treatment decisions for pediatric TSC patients.
  • The tool supports clinicians in managing DRE risk in TSC, enhancing patient care.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
274
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
582
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632